The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).
 
Maria E. Cabanillas
Honoraria - Loxo/Lilly
Consulting or Advisory Role - Bayer; Exelixis; Ignyta; Lilly; Loxo
Research Funding - Eisai; Exelixis; Kura Oncology; Merck; Roche/Genentech
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - Bayer; Blueprint Medicines; C4 Therapeutics; Elevation Oncology; Genentech; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Regeneron; Turning Point Therapeutics
Research Funding - Bayer (Inst); Elevation Oncology (Inst); Hengrui Therapeutics (Inst); Linnaeus Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Relay Therapeutics (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Marcia S. Brose
Honoraria - Bayer; Eisai; Lilly
Consulting or Advisory Role - AADi; Bayer; Blueprint Medicines; Eisai; Exelixis; Lilly; Loxo
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Eisai (Inst); Exelixis (Inst); Lilly (Inst); Loxo (Inst)
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Mohammed Almubarak
No Relationships to Disclose
 
Jessica R Bauman
Consulting or Advisory Role - BeiGene; Blueprint Medicines; Janssen; Lilly; Merck; Mirati Therapeutics; Pfizer; Turning Point Therapeutics
 
Michela Casanova
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Pfizer; Servier
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); PathomIQ
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cadila Pharmaceuticals (I); EcoR1 Capital; Genome Insight; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; Mundipharma; Oxford BioTherapeutics; Seagan; SpringWorks Therapeutics
Research Funding - ADC Therapeutics (Inst); ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Day One Therapeutics (Inst); Dynavax Technologies (Inst); Elevation Oncology (Inst); Genome & Company (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Moderna Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Bayer
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Lilly; Merck; Roche
Consulting or Advisory Role - AstraZeneca; BMS/Ono; IMBdx; Janssen; Lilly; Merck; Pfizer; Roche; Takeda
Research Funding - AstraZeneca; Lunit; Merck
Travel, Accommodations, Expenses - Novartis
 
Serge Leyvraz
Consulting or Advisory Role - Bayer
Travel, Accommodations, Expenses - Bayer
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche; Sanofi
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); CANbridge Pharmaceuticals (Inst); Jacobio (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)
 
Ricarda Norenberg
Employment - Bayer
 
Vadim Bernard-Gauthier
Employment - Bayer
 
Chiara E. Mussi
Employment - Bayer
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Infinity Pharmaceuticals; Janssen; Liberum; MedaCorp; Medscape; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Steven G. Waguespack
Honoraria - Bayer
Consulting or Advisory Role - Bayer